24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 1 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 19 , , 1
      International Journal of Clinical Oncology
      Springer Singapore
      Non-small cell lung cancer, Chemotherapy, Kinase inhibitor, Programed cell death-1 inhibitor, Programed death-ligand 1 inhibitor, Guideline

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50%, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.

          Related collections

          Most cited references85

          • Record: found
          • Abstract: found
          • Article: not found

          Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

          First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

            Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

              The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients.
                Bookmark

                Author and article information

                Contributors
                +81925413231 , setocruise@gmail.com
                Journal
                Int J Clin Oncol
                Int. J. Clin. Oncol
                International Journal of Clinical Oncology
                Springer Singapore (Singapore )
                1341-9625
                1437-7772
                2 May 2019
                2 May 2019
                2019
                : 24
                : 7
                : 731-770
                Affiliations
                [1 ]ISNI 0000 0004 1763 1087, GRID grid.412857.d, Internal Medicine III, , Wakayama Medical University, ; Wakayama, Japan
                [2 ]ISNI 0000 0001 1302 4472, GRID grid.261356.5, Department of Hematology, Oncology and Respiratory Medicine, , Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, ; Okayama, Japan
                [3 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Thoracic Oncology, , Shizuoka Cancer Center, ; Shizuoka, Japan
                [4 ]ISNI 0000 0001 0943 978X, GRID grid.27476.30, Department of Respiratory Medicine, , Nagoya University Graduate School of Medicine, ; Aichi, Japan
                [5 ]ISNI 0000 0004 1764 9308, GRID grid.416948.6, Osaka City General Hospital, ; Osaka, Japan
                [6 ]ISNI 0000 0001 2168 5385, GRID grid.272242.3, Department of Thoracic Oncology, , National Cancer Center Hospital, ; Tokyo, Japan
                [7 ]ISNI 0000 0004 0618 8403, GRID grid.415740.3, Clinical Research Center, Department of Thoracic Oncology and Medicine, , National Hospital Organization Shikoku Cancer Center, ; Ehime, Japan
                [8 ]ISNI 0000 0004 0377 8969, GRID grid.416203.2, Department of Internal Medicine, , Niigata Cancer Center Hospital, ; Niigata, Japan
                [9 ]ISNI 0000 0000 8638 2724, GRID grid.252427.4, Respiratory Center, , Asahikawa Medical University Hospital, ; Hokkaido, Japan
                [10 ]ISNI 0000 0004 4674 3774, GRID grid.415611.6, National Hospital Organization Kinki-chuo Chest Medical Center, ; Osaka, Japan
                [11 ]ISNI 0000 0000 8661 1590, GRID grid.411621.1, Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, , Shimane University Faculty of Medicine, ; Shimane, Japan
                [12 ]ISNI 0000 0001 2172 5041, GRID grid.410783.9, Department of Thoracic Oncology, , Kansai Medical University Hospital, ; Osaka, Japan
                [13 ]GRID grid.417755.5, Department of Thoracic Oncology, , Hyogo Cancer Center, ; Hyogo, Japan
                [14 ]ISNI 0000 0000 8864 3422, GRID grid.410714.7, Advanced Cancer Translational Research Institute, , Showa University, ; Tokyo, Japan
                [15 ]ISNI 0000 0001 2107 4242, GRID grid.266100.3, Department of Surgery, , University of California San Diego, ; California, USA
                [16 ]ISNI 0000 0001 2168 5385, GRID grid.272242.3, National Cancer Center Hospital East, ; Chiba, Japan
                [17 ]ISNI 0000 0001 2173 8328, GRID grid.410821.e, Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, , Nippon Medical School, ; Tokyo, Japan
                [18 ]ISNI 0000 0004 0378 6088, GRID grid.412167.7, First Department of Medicine, , Hokkaido University Hospital, ; Hokkaido, Japan
                [19 ]GRID grid.470350.5, Thoracic Oncology, , National Hospital Organization Kyushu Cancer Center, ; Fukuoka, Japan
                [20 ]GRID grid.415479.a, Department of Thoracic Oncology and Respiratory Medicine, , Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, ; Tokyo, Japan
                [21 ]ISNI 0000 0004 0404 8415, GRID grid.411248.a, Kyushu University Hospital, ; Fukuoka, Japan
                [22 ]ISNI 0000 0001 2308 3329, GRID grid.9707.9, Regional Respiratory Symptomatology, , Kanazawa University Graduate School of Medical Science, ; Kanazawa, Japan
                [23 ]ISNI 0000 0001 2242 4849, GRID grid.177174.3, Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, , Kyushu University, ; Fukuoka, Japan
                [24 ]ISNI 0000 0001 2168 5385, GRID grid.272242.3, Department of Thoracic Oncology, , National Cancer Center Hospital East, ; Chiba, Japan
                [25 ]ISNI 0000 0001 1033 6139, GRID grid.268441.d, Department of Biostatistics, , Yokohama City University School of Medicine, ; Kanagawa, Japan
                [26 ]Japan Federation of Cancer Patient Groups, Tokyo, Japan
                [27 ]Japan Lung Cancer Alliance, Tokyo, Japan
                [28 ]ISNI 0000 0004 0372 2033, GRID grid.258799.8, Department of Biomedical Statistics and Bioinformatics, , Kyoto University Graduate School of Medicine, ; Kyoto, Japan
                [29 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Shizuoka Cancer Center, ; Shizuoka, Japan
                [30 ]ISNI 0000 0000 9613 6383, GRID grid.411790.a, Division of Pulmonary Medicine, Allergry and Rheumatology, Department of Internal Medicine, , Iwate Medical University School of Medicine, ; Iwate, Japan
                Article
                1431
                10.1007/s10147-019-01431-z
                6545178
                31049758
                96c776d4-0ef4-49e5-81ef-9c83ffecd3d4
                © The Author(s) 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 22 February 2019
                : 6 March 2019
                Funding
                Funded by: Japanese Lung Cancer Society
                Categories
                Special Article
                Custom metadata
                © Japan Society of Clinical Oncology 2019

                non-small cell lung cancer,chemotherapy,kinase inhibitor,programed cell death-1 inhibitor,programed death-ligand 1 inhibitor,guideline

                Comments

                Comment on this article